Hyperprolactinaemia with amisulpride | Zendy

Rajnish Raj | Zendy; BalwantSingh Sidhu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hyperprolactinaemia with amisulpride

Author(s) -

Rajnish Raj,

BalwantSingh Sidhu

Publication year - 2008

Publication title -

indian journal of psychiatry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.485

H-Index - 34

eISSN - 1998-3794

pISSN - 0019-5545

DOI - 10.4103/0019-5545.39761

Subject(s) - amisulpride , hyperprolactinaemia , postsynaptic potential , pharmacology , dopamine , sulpiride , agonist , dopamine receptor d2 , medicine , endocrinology , receptor , prolactin , neuroscience , clozapine , psychology , psychiatry , schizophrenia (object oriented programming) , dopaminergic , hormone

Amisulpride, a substituted benzamide derivative, is a second-generation antipsychotic that preferentially binds to D2/D3 receptors in limbic rather than striatal structures. High dosage preferentially antagonizes postsynaptic receptors, resulting in reduced dopamine transmission; and low dosage blocks presynaptic receptors, resulting in enhanced transmission. Hyperprolactinaemia may occur in patients receiving amisulpride at low dose of 50 mg/day and results in galactorrhoea, amenorrhea and sexual dysfunction. The symptom ameliorates on withdrawing the drug, switching to non-prolactin-elevating drugs, and timely management with dopamine agonist.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research